Interpace Biosciences Simplifies Capital Structure, Becomes Debt-Free, and Targets Nasdaq Uplisting Amidst Revenue Growth

summarizeSummary

Interpace Biosciences announced preliminary 2025 revenue growth and 2026 guidance, alongside a significant capital structure simplification through the conversion of all preferred stock to common shares. The company is now debt-free and plans to seek an uplisting to Nasdaq.

check_boxKey Events

• Preliminary 2025 Revenue Growth

  The company reported preliminary and unaudited 2025 revenue of $38-39 million, with thyroid testing revenue growing approximately 21% over 2024.

• 2026 Revenue Guidance Initiated

  Interpace Biosciences provided initial full-year 2026 revenue guidance of approximately $40 million, representing 16% growth in thyroid testing revenue over 2025.

• Preferred Stock Conversion Completed

  All outstanding Series C Preferred Stock was converted into approximately 23.27 million common shares at a conversion price of $2.02 per share, significantly simplifying the capital structure.

• Debt-Free Balance Sheet Achieved

  The company confirmed it is now debt-free, having paid off 100% of its outstanding debt in December.

auto_awesomeAnalysis

This 8-K signals a significant strategic pivot for Interpace Biosciences, addressing key structural issues that likely contributed to its low market valuation. The conversion of all preferred stock, while highly dilutive to existing common shareholders (increasing shares outstanding by over 500%), fundamentally simplifies the company's capital structure. This, combined with becoming debt-free, significantly de-risks the balance sheet and improves financial transparency. The preliminary revenue growth and positive 2026 guidance provide a strong operational backdrop, suggesting the company's core thyroid testing business is performing well. The stated intent to uplist to Nasdaq is a major positive, potentially increasing liquidity, institutional interest, and overall investor confidence. Investors should monitor the progress of the Nasdaq uplisting and the company's ability to execute on its growth guidance.